---
id: 230
title: Clostridioides difficile Infection (CDI)
category: clinical_syndromes
subcategory: gastrointestinal
tags: [C-diff, CDI, pseudomembranous-colitis, vancomycin, fidaxomicin, FMT]
difficulty: high
---

## Question

How is *C. difficile* infection managed? Use **"Initial: Vancomycin 125mg QID × 10d, Recurrent: Fidaxomicin or FMT"** framework.

## Answer

### **Definition:**

***Clostridioides difficile* Infection (CDI):**
- **Toxin-producing anaerobic bacteria** → colitis
- **Most common healthcare-associated infection** (US)

### **Risk Factors:**

**Major:**
- **Antibiotic exposure** (especially fluoroquinolones, clindamycin, cephalosporins, carbapenems)
- **Hospitalization, long-term care**
- **Age >65 years**
- **PPI use** (↑risk 2-3×)
- **Immunosuppression**

### **Clinical Presentation:**

**Severity Spectrum:**

**Mild-Moderate:**
- **Watery diarrhea** (≥3 unformed stools/24h)
- **Lower abdominal cramping**
- **Low-grade fever**
- **WBC <15,000**

**Severe:**
- **≥1 of:**
  - WBC ≥15,000
  - Cr ≥1.5× baseline
- **Systemic toxicity** (fever, tachycardia, hypotension)

**Fulminant (Severe-Complicated):**
- **Hypotension, shock, ileus, megacolon**
- **WBC >35,000 or <2,000**
- **Lactate >2.2 mmol/L**
- **Peritonitis, perforation**
- **ICU admission**

### **Diagnosis:**

**Indications for Testing:**
- **≥3 unformed stools in 24h** + risk factors
- **Do NOT test:** Formed stools, test of cure, asymptomatic patients

**Testing Strategies:**

**2-Step Algorithm (Preferred):**
1. **GDH (glutamate dehydrogenase) antigen + toxin EIA**
   - **Both positive:** CDI confirmed
   - **GDH+, toxin-:** Proceed to step 2
   - **Both negative:** CDI ruled out
2. **NAAT (PCR)** if discordant
   - **Positive:** CDI confirmed
   - **Negative:** CDI ruled out

**NAAT Alone:**
- **High sensitivity** (detects colonization + infection)
- **May overdiagnose** (10-15% asymptomatic carriers)

**Stool Toxin EIA:**
- **Low sensitivity** (~75%), high specificity
- **Not recommended alone**

### **Treatment:**

**Initial Episode:**

**Mild-Moderate OR Severe (Non-Fulminant):**
- **Vancomycin 125mg PO QID × 10 days** (first-line)
- **Alternative:** Fidaxomicin 200mg PO BID × 10 days (lower recurrence, but expensive)

**Fulminant (Severe-Complicated):**
- **Vancomycin 500mg PO/NG QID** (higher dose)
- **+ Metronidazole 500mg IV q8h** (for systemic absorption if ileus)
- **+ Vancomycin enema 500mg in 100 mL NS q6h** (if ileus, complete obstruction)

**If Cannot Take PO/NG:**
- **Vancomycin enema** + **metronidazole IV**

**First Recurrence (13-40%):**
- **Vancomycin 125mg PO QID × 10 days** (if metronidazole used initially)
- **Fidaxomicin 200mg PO BID × 10 days** (preferred, lower 2nd recurrence)
- **Vancomycin taper/pulse:** 125mg QID × 10-14d → BID × 7d → daily × 7d → every 2-3 days × 2-8 weeks

**Second Recurrence (≥2 Recurrences, 35-65%):**
- **Fidaxomicin 200mg PO BID × 10 days** (if not used previously)
- **Vancomycin taper/pulse** (extended regimen)
- **Fecal microbiota transplantation (FMT)** (80-90% cure rate)
- **Bezlotoxumab 10 mg/kg IV × 1** (monoclonal antibody to toxin B, reduces recurrence by 40%)

**Surgical Management:**

**Indications:**
- **Fulminant CDI with:** Peritonitis, perforation, toxic megacolon
- **Refractory shock** (despite medical therapy)
- **WBC >50,000, lactate ≥5 mmol/L**

**Procedure:**
- **Subtotal colectomy with end ileostomy** (traditional)
- **Diverting loop ileostomy + colonic lavage + vancomycin** (alternative, preserves colon)

**Mortality:** 30-50% (fulminant CDI requiring surgery)

### **Adjunctive Therapies:**

**Bezlotoxumab:**
- **Monoclonal antibody to toxin B**
- **10 mg/kg IV × 1** (given during CDI treatment)
- **Reduces recurrence by 40%** (especially high-risk patients)
- **Indications:** Age >65, severe CDI, ≥2 recurrences, immunosuppressed

**Fecal Microbiota Transplantation (FMT):**
- **80-90% cure** for recurrent CDI (≥2 recurrences)
- **Methods:** Colonoscopy, capsules, enema
- **Restores gut microbiome**
- **FDA-approved FMT products available**

### **Prevention:**

**Antibiotic Stewardship:**
- **Avoid unnecessary antibiotics** (especially fluoroquinolones, clindamycin)

**Infection Control:**
- **Contact precautions** (private room, gown/gloves)
- **Hand hygiene:** SOAP AND WATER (alcohol gel does NOT kill spores)
- **Bleach disinfection** (1:10 bleach solution for environmental surfaces)

**Probiotics:**
- **NOT recommended** for CDI prevention (insufficient evidence)

**PPI Discontinuation:**
- **If not indicated** (↑CDI risk)

### **Monitoring:**

**Do NOT Test for Cure:**
- **NAAT may remain positive** × weeks to months (non-viable organisms)
- **Assess clinical improvement**

**Recurrence Risk:**
- **First episode:** 13-40%
- **After 1st recurrence:** 35-65%
- **After 2nd recurrence:** 45-65%

## Key Points

### **Vancomycin 125mg QID × 10d:**
- **First-line** for initial episode, first recurrence
- **PO only** (not absorbed, acts locally in colon)

### **Fidaxomicin for Recurrence:**
- **200mg PO BID × 10 days**
- **Lower recurrence** than vancomycin (15% vs 25%)

### **FMT for ≥2 Recurrences:**
- **80-90% cure rate**
- **Restores gut microbiome**

### **Fulminant = High-Dose Vanc + IV Metronidazole:**
- **Vancomycin 500mg PO QID**
- **+ Metronidazole 500mg IV q8h**
- **± Vancomycin enema** (if ileus)

### **Surgery if Fulminant + Shock:**
- **Subtotal colectomy**
- **High mortality** (30-50%)

### **Clinical Pearls:**
- **Initial:** Vancomycin 125mg PO QID × 10 days (fidaxomicin if high recurrence risk)
- **First recurrence:** Vancomycin OR fidaxomicin
- **≥2 recurrences:** FMT (80-90% cure) OR fidaxomicin OR vancomycin taper/pulse
- **Fulminant:** Vancomycin 500mg PO QID + metronidazole 500mg IV q8h ± vancomycin enema
- **Bezlotoxumab:** Reduces recurrence (high-risk patients)
- **Hand hygiene:** SOAP AND WATER (alcohol does NOT kill spores)
- **Do NOT test for cure** (NAAT remains positive)

## Sources

- [IDSA/SHEA: *Clostridioides difficile* Infection Guidelines 2024]
- [NEJM: Management of CDI 2024]

## Media

N/A
